MedPath

Solid Biosciences Inc.

Solid Biosciences Inc. logo
🇺🇸United States
Ownership
Public
Established
2014-01-01
Employees
101
Market Cap
$353.1M
Website
http://www.solidbio.com
finance.yahoo.com
·

Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News

Ultragenyx Pharmaceutical Inc. (RARE) focuses on novel treatments for rare genetic diseases, with products like Crysvita and Mepsevii. It collaborates globally and reported a market cap of $4.031B, with a YTD return of 3.26% as of January 8, 2025.
biospace.com
·

Solid Biosciences Announces FDA IND Clearance for First-in-Human Gene Therapy SGT-212 for Friedreich’s Ataxia

Solid Biosciences' SGT-212, a novel AAV-based gene therapy for Friedreich’s ataxia, targets CNS and cardiac symptoms via dual administration. FDA cleared its IND, with a Phase 1b trial expected in 2H 2025. The therapy aims to restore frataxin levels, addressing FA's neurological and cardiac manifestations.
stocktitan.net
·

Solid Biosciences' Revolutionary Dual-Route Gene Therapy for Friedreich's Ataxia Gains FDA IND Clearance

Solid Biosciences received FDA IND clearance for SGT-212, a novel gene therapy for Friedreich’s ataxia, targeting both neurologic and cardiac symptoms via dual administration. A Phase 1b trial is set for 2H 2025, aiming to treat the disease's full spectrum.
marketscreener.com
·

Solid Biosciences Inc. Announces FDA IND Clearance for First Novel AAV-Based Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc. received FDA clearance for SGT-212, a novel AAV-based gene therapy for Friedreich’s ataxia (FA), targeting both systemic and cerebellar delivery. SGT-212 aims to address FA's neurologic and systemic manifestations, with a Phase 1b trial starting in late 2025 to assess safety and tolerability over five years.
marketscreener.com
·

Solid Biosciences Announces FDA IND Clearance for First-In Novel Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc. announced FDA clearance for SGT-212, a novel gene therapy for Friedreich’s ataxia, targeting CNS and cardiac symptoms via dual administration. A Phase 1b trial is expected in 2H 2025. SGT-212 aims to restore frataxin levels, addressing disease progression and symptoms.
morningstar.com
·

Solid Biosciences Announces FDA IND Clearance for First-In-Human Trial of SGT-212 Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc. announced FDA clearance for SGT-212, a novel AAV-based gene therapy for Friedreich’s ataxia (FA), targeting CNS and cardiac symptoms via dual administration. A Phase 1b trial is expected in 2H 2025. SGT-212 aims to restore frataxin levels, addressing FA's neurological and cardiac manifestations.
globenewswire.com
·

Solid Biosciences Announces FDA IND Clearance for SGT-212, a Novel AAV-Based Gene Therapy Targeting Friedreich’s Ataxia

SGT-212, a novel AAV-based gene therapy by Solid Biosciences, targets Friedreich’s ataxia (FA) by delivering full-length frataxin to the cerebellum and heart via dual administration. A Phase 1b trial is set for 2H 2025, aiming to address FA's neurological and cardiac symptoms. The FDA has cleared its IND application, marking a significant step towards treating FA's full spectrum.
globenewswire.com
·

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Inc. was added to the Nasdaq Biotechnology Index on Dec. 23, 2024, reflecting its classification as a biotechnology or pharmaceutical company. The index tracks performance of eligible securities on Nasdaq, adhering to criteria like market capitalization and trading volume.
investing.com
·

Solid Biosciences' SWOT analysis: gene therapy stock's potential in DMD treatment

Solid Biosciences Inc., focusing on Duchenne muscular dystrophy (DMD) treatments, is advancing with SGT-003, a gene therapy candidate. With a strong financial position and innovative capsid technology, it aims to disrupt the DMD treatment landscape. Despite operating at a loss, its potential for superior efficacy and safety profiles positions it as a key player in the gene therapy market.
© Copyright 2025. All Rights Reserved by MedPath